DE60016242D1 - Verfahren zur diagnose oder prognose von altersbedingter maculadegeneration - Google Patents

Verfahren zur diagnose oder prognose von altersbedingter maculadegeneration

Info

Publication number
DE60016242D1
DE60016242D1 DE60016242T DE60016242T DE60016242D1 DE 60016242 D1 DE60016242 D1 DE 60016242D1 DE 60016242 T DE60016242 T DE 60016242T DE 60016242 T DE60016242 T DE 60016242T DE 60016242 D1 DE60016242 D1 DE 60016242D1
Authority
DE
Germany
Prior art keywords
age
subject
macular degeneration
related macular
diagnosing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60016242T
Other languages
English (en)
Other versions
DE60016242T2 (de
Inventor
Giesbert Richard
Roger Nitsch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Evotec Neurosciences GmbH
Original Assignee
Evotec Neurosciences GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evotec Neurosciences GmbH filed Critical Evotec Neurosciences GmbH
Publication of DE60016242D1 publication Critical patent/DE60016242D1/de
Application granted granted Critical
Publication of DE60016242T2 publication Critical patent/DE60016242T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/8139—Cysteine protease (E.C. 3.4.22) inhibitors, e.g. cystatin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes
DE60016242T 1999-09-01 2000-09-01 Verfahren zur diagnose oder prognose von altersbedingter maculadegeneration Expired - Fee Related DE60016242T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP99117198 1999-09-01
EP99117198 1999-09-01
EP00101921 2000-02-01
EP00101921 2000-02-01
PCT/EP2000/008554 WO2001016364A2 (en) 1999-09-01 2000-09-01 Methods of diagnosing or prognosticating age-related macular degeneration

Publications (2)

Publication Number Publication Date
DE60016242D1 true DE60016242D1 (de) 2004-12-30
DE60016242T2 DE60016242T2 (de) 2005-12-01

Family

ID=26070484

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60016242T Expired - Fee Related DE60016242T2 (de) 1999-09-01 2000-09-01 Verfahren zur diagnose oder prognose von altersbedingter maculadegeneration

Country Status (5)

Country Link
US (1) US20070117122A1 (de)
EP (1) EP1210464B1 (de)
AT (1) ATE283487T1 (de)
DE (1) DE60016242T2 (de)
WO (1) WO2001016364A2 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
WO2006096561A2 (en) 2005-03-04 2006-09-14 Duke University Genetic variants increase the risk of age-related macular degeneration
KR101354876B1 (ko) * 2005-06-08 2014-02-18 유니버시티 오브 피츠버그 - 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 염색체 10ｑ26상의 연령-관련 황반병증(ＡＲＭ)에 대한감수성 유전자
EP1941061A1 (de) * 2005-11-02 2008-07-09 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Zur erkennung und zum testen altersbedingter makuladegeneration entstandenes verfahren (mert-armd)
CN101506236B (zh) 2005-11-30 2012-12-12 雅培制药有限公司 抗淀粉样β蛋白的单克隆抗体及其用途
BRPI0619249A2 (pt) 2005-11-30 2011-09-20 Abbott Lab anticorpos anti-globulÈmeros-aß, frações que se ligam a antìgeno destes, hibridomas correspondentes, ácidos nucléicos, vetores, células hospedeiras, métodos de produzir os ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos de usar os ditos anticorpos
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2486928A1 (de) 2007-02-27 2012-08-15 Abbott GmbH & Co. KG Verfahren zur Behandlung von Amyloidosen
WO2008110283A2 (en) * 2007-03-14 2008-09-18 Dsm Ip Assets B.V. Method for prevention of age-related macular degeneration (amd)
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
AU2008311365B2 (en) * 2007-10-05 2015-03-12 Ac Immune S.A. Humanized antibody
CN101883790B (zh) 2007-10-05 2015-09-09 基因技术公司 抗淀粉样蛋白β抗体在眼病中的用途
MX360403B (es) 2010-04-15 2018-10-31 Abbvie Inc Proteinas de union a amiloide beta.
RU2607368C2 (ru) 2010-07-30 2017-01-10 Ац Иммуне С.А. Безопасные и функциональные гуманизированные антитела
JP6147665B2 (ja) 2010-08-14 2017-06-14 アッヴィ・インコーポレイテッド アミロイドベータ結合タンパク質
EP2497490A1 (de) * 2011-03-07 2012-09-12 Bioquanta Verfahren zur Diagnose und/oder Behandlung von Sterilität
JP5721150B2 (ja) * 2013-03-14 2015-05-20 学校法人 埼玉医科大学 加齢黄斑変性症の発症リスクの予測方法
US20240035033A1 (en) * 2022-07-29 2024-02-01 Chung-Ang University Industry-Academic Cooperation Foundation Prevention and treatment of age-related macular degeneration through suppression of cathepsin s expression

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3724581A1 (de) * 1987-07-24 1989-02-02 Gruenenthal Gmbh Dna-sequenzen, die fuer proteine mit den biologischen eigenschaften des cystatin c codieren, herstellung dieser dna-sequenzen, expression des cystatin c sowie dieses enthaltende pharmazeutische zubereitungen
US5231000A (en) * 1987-10-08 1993-07-27 The Mclean Hospital Antibodies to A4 amyloid peptide
US5262332A (en) * 1989-04-05 1993-11-16 Brigham And Women's Hospital Diagnostic method for Alzheimer's disease: examination of non-neural tissue
WO1991016628A1 (en) * 1990-04-24 1991-10-31 The Regents Of The University Of California Purification, detection and methods of use of protease nexin-2
US5981471A (en) * 1997-02-06 1999-11-09 Entremed, Inc. Compositions and methods for inhibiting cellular proliferation

Also Published As

Publication number Publication date
EP1210464B1 (de) 2004-11-24
EP1210464A2 (de) 2002-06-05
DE60016242T2 (de) 2005-12-01
WO2001016364A2 (en) 2001-03-08
ATE283487T1 (de) 2004-12-15
WO2001016364A3 (en) 2002-03-14
US20070117122A1 (en) 2007-05-24

Similar Documents

Publication Publication Date Title
DE60016242D1 (de) Verfahren zur diagnose oder prognose von altersbedingter maculadegeneration
Schütt et al. Dogs with cognitive dysfunction as a spontaneous model for early Alzheimer’s disease: a translational study of neuropathological and inflammatory markers
DE60233485D1 (de) Verfahren zur diagnose, behandlung und prävention von knochenverlust
DE60239470D1 (de) Verfahren zur bewertung pathologischer krankheitszustände unter verwendung extrazellulärer rna
WO2005055810A3 (en) Risk markers for cardiovascular disease
ATE312946T1 (de) Verfahren und vorrichtung zur bestimmung der gewebespezifität von freier dna in körperflüssigkeiten
DE60325617D1 (de) Verfahren zur diagnose von bauchspeicheldrüsenkrebs
WO2004046729A3 (en) Bodily fluid markers of tissue hypoxia
ATE474227T1 (de) Bestimmung von felinem und caninem probnp
ATE514948T1 (de) In vitro verfahren zur diagnose von neurodegenerativen erkrankungen
RU2008103988A (ru) Способ диагностики рассеяного склероза
DE60332538D1 (de) Oligosaccharid-biomarker für mucopolysaccharidosen und andere verwandte störungen
DE69729954D1 (de) Identifizierungsverfahren für Substanzen die an das Pyk2 Polypeptid binden
DE60122673D1 (de) Methoden zur diagnose und behandlung von herzkrankheiten
ATE286253T1 (de) Methoden zur diagnose oder prognose der alzheimerschen krankheit
ATE392619T1 (de) Verfahren zur diagnose von synovialen oder osteoartikulären erkrankungen
ATE225405T1 (de) Verfahren zur diagnose oder zur prognose von alzheimer krankheit: therapeutische zusammensetzung zur verhinderung oder zur behandlung von alzheimer krankheit
ATE343793T1 (de) Methode zur diagnostizierung, prognose oder evaluation von behandlung der depressionen, basiert auf erhöhte neurotrophin concentrationen in zerebrospinale flüssigkeit.
ATE499611T1 (de) Verfahren zur diagnose von erkrankungen unter bestimmung von apolipoprotein c-i
DE60033646D1 (de) Methoden zur diagnostizierung oder zur behandlung der alzheimer-krankheit
DE69734890D1 (de) Rdgb-proteine
ATE485515T1 (de) Verfahren zur diagnose einer person mit multipler sklerose
WO2008037720A3 (en) Means and methods for diagnosing and/or treating a subject at risk of developing heart failure
Delacourte et al. The Biochemical Spreading of Tau and Amyloid-Precursor Protein Pathologies in Aging and Sporadic Alzheimer’s Disease
DE602005023973D1 (de) Verfahren zur diagnose von chronischem stress und verwandten erkrankungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee